To summarize, we have shown that a single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in HNF1A- and GCK-MODY than in T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.